Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
Go back to Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma| (NASDAQ: RAIN) | Delayed: 1.97 -0.01 (0.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.98 | 52 Week High | $ | |||
| Open | $2.02 | 52 Week Low | $ | |||
| Day High | $2.04 | P/E | N/A | |||
| Day Low | $1.92 | EPS | $ | |||
| Volume | 20,625 | |||||
